These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6276726)

  • 1. Action of naloxone and naltrexone in different types of psychoses.
    Volavka J
    Mod Probl Pharmacopsychiatry; 1981; 17():202-12. PubMed ID: 6276726
    [No Abstract]   [Full Text] [Related]  

  • 2. [Etiologic and therapeutic significance of endorphins in endogenous psychoses].
    Naber D
    Nervenarzt; 1983 Nov; 54(11):573-7. PubMed ID: 6318141
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of naloxone on the state of patients with endogenous psychoses.
    Lideman RR; Panteleeva GP; Tsutsul'kovskaya MYa ; Vartanyan FE; Belyaev BS
    Neurosci Behav Physiol; 1984; 14(6):471-5. PubMed ID: 6097836
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
    Schecter A
    Am J Drug Alcohol Abuse; 1980; 7(1):1-18. PubMed ID: 6254356
    [No Abstract]   [Full Text] [Related]  

  • 5. Naltrexone, opiate addiction, and endorphins.
    Gold MS; Dackis CA; Pottash AL; Sternbach HH; Annitto WJ; Martin D; Dackis MP
    Med Res Rev; 1982; 2(3):211-46. PubMed ID: 6289026
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of naloxone in schizophrenic psychoses and manic syndromes.
    Verhoeven WM; van Praag HM; de Jong JT
    Neuropsychobiology; 1981; 7(3):159-68. PubMed ID: 7231653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nontolerance to the opioid antagonism of naltrexone.
    Kleber HD; Kosten TR; Gaspari J; Topazian M
    Biol Psychiatry; 1985 Jan; 20(1):66-72. PubMed ID: 2981129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some observations on the opiate peptides and schizophrenia.
    Watson SJ; Akil H; Berger PA; Barchas JD
    Arch Gen Psychiatry; 1979 Jan; 36(1):35-41. PubMed ID: 216330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of naloxone to reduce manic symptoms.
    Davis GC; Extein I; Reus VI; Hamilton W; Post RM; Goodwin FK; Bunney WE
    Am J Psychiatry; 1980 Dec; 137(12):1583-5. PubMed ID: 7435717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New and experimental therapeutic roles for naloxone and related opioid antagonists.
    McNicholas LF; Martin WR
    Drugs; 1984 Jan; 27(1):81-93. PubMed ID: 6319107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatric implications of endorphin research.
    Mackay AV
    Br J Psychiatry; 1979 Nov; 135():470-3. PubMed ID: 231991
    [No Abstract]   [Full Text] [Related]  

  • 12. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram.
    Petrakis IL; Nich C; Ralevski E
    Schizophr Bull; 2006 Oct; 32(4):644-54. PubMed ID: 16887890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pain sensitivity and endorphins in functional psychoses.
    Davis GC; Buchsbaum MS
    Mod Probl Pharmacopsychiatry; 1981; 17():97-108. PubMed ID: 6276733
    [No Abstract]   [Full Text] [Related]  

  • 14. Naloxone and naltrexone in mental illness and tardive dyskinesia.
    Volavka J; Anderson B; Koz G
    Ann N Y Acad Sci; 1982; 398():97-102. PubMed ID: 6760771
    [No Abstract]   [Full Text] [Related]  

  • 15. Withdrawal from endogenous opiates.
    Julius DA
    Am J Psychiatry; 1979 Mar; 136(3):358-9. PubMed ID: 420348
    [No Abstract]   [Full Text] [Related]  

  • 16. [Endorphins and endogenous psychoses].
    Naber D; Pickar D
    Nervenarzt; 1984 Jul; 55(7):378-81. PubMed ID: 6089011
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of naltrexone in the treatment of schizophrenia.
    Gitlin MJ; Gerner RH; Rosenblatt M
    Psychopharmacology (Berl); 1981; 74(1):51-3. PubMed ID: 6791204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone in the treatment of opiate dependence.
    Resnick RB; Washton AM; Thomas MA; Kestenbaum RS
    NIDA Res Monogr; 1978; (19):321-32. PubMed ID: 218108
    [No Abstract]   [Full Text] [Related]  

  • 19. Behavioral effects of opioid receptor antagonists in psychopathologic states.
    Janowsky DS; Judd LL; Huey LY; Risch SC; Segal DS
    Psychiatr Clin North Am; 1983 Sep; 6(3):403-14. PubMed ID: 6316300
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of naltrexone on mood and neuroendocrine function in normal adult males.
    Mendelson JH; Ellingboe J; Keuhnle JC; Mello NK
    Psychoneuroendocrinology; 1978 Oct; 3(3-4):231-6. PubMed ID: 219434
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.